
The phase 3 studies looked at 1,635 people and compared the new insulin with a standard insulin glargine. It appeared effective for both type 1 and type 2 diabetes.
Read more
The phase 3 studies looked at 1,635 people and compared the new insulin with a standard insulin glargine. It appeared effective for both type 1 and type 2 diabetes.
Read more